A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.

NCT01737359 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus Infection

Interventions

DRUG: amdoxovir 300 mg bid
DRUG: amdoxovir 500 mg bid
DRUG: tenofovir DF 300 mg qd

Sponsor

RFS Pharma, LLC